Tepotinib not checked
Merck KGaA, Darmstadt, Germany · MSC2156119J · EMD 1214063
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.”In the company’s words, NCT02864992 on ClinicalTrials.gov
- Tested for
- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
- Main trialPhase 2
- “This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a…”In the company’s words, NCT02864992 on ClinicalTrials.gov
- Other names
- MSC2156119J · EMD 1214063
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 16 May 2022 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | |
| Phase 2Terminated | 14 Mar 2022 | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | |
| Phase 2Completed | 11 May 2023 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | |
| Phase 1/2Completed | 12 Dec 2017 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | |
| Phase 1/2Completed | 5 Feb 2018 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | |
| Phase 1/2Completed | 14 Feb 2018 | c-Met Second-Line Hepatocellular Carcinoma | |
| Phase 1Completed | 31 Oct 2015 | First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors | |
| Phase 1Completed | 31 Mar 2016 | Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers | |
| Phase 1Completed | 2 Jul 2018 | Effect of a Proton Pump Inhibitor on the PK of Tepotinib | |
| Phase 1Completed | 27 Aug 2018 | Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | |
| Phase 1Completed | 25 Oct 2018 | Effect of Tepotinib on PK of CYP3A Substrate Midazolam | |
| Phase 1Completed | 5 Feb 2019 | Tepotinib Hepatic Impairment Trial | |
| Phase 1Completed | 16 Dec 2019 | Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib | |
| Phase 1Completed | 6 May 2022 | Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants | |
| Phase 1Completed | 5 Jul 2022 | Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile | |
| Phase 2Authorised | not given | Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy. | |
| Phase 3Authorised | not given | IFCT-2404 COMET A Randomized Controlled Trial of Tepotinib vs Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer | |
| Phase 2/3Authorised | not given | DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026